ArticleCureus2025
Sero-Surveillance to Evaluate Trends in the Transmission of SARS-CoV-2 in a Central Indian District.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective The actual community burden of SARS-CoV-2 is undervalued, as the estimates are just the symptomatic infections. The acute phase of the pandemic has waned, and the analytical comparison of infection spread through repeated sero-epidemiological studies is important in the formulation of effective public health strategies. This study investigated the level of seroprevalence of IgG antibodies for the SARS-CoV-2 virus in the Nagpur district, Maharashtra, India. Materials and methods The present cross-sectional survey was conducted over three months from September to November 2021 by carrying out a door-to-door survey involving 6129 participants. Among them, 3131 were from municipal areas, while the rest were from non-municipal regions. Data collection was facilitated using Google Forms (Google LLC, Mountain View, California, United States). Venous blood samples were collected, and SARS-CoV-2 antibodies were detected using the COVID KAVACH IgG enzyme-linked immunosorbent assay (ELISA) kit (developed by the National Institute of Virology (NIV), Pune, India). The information collected was then cleaned, coded, and analyzed using Epi Info software (Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA). Results The seroprevalence rate was found to be 80% in the whole district. Females had a higher seroprevalence rate in both areas than males. The population aged 60 years and above had the highest seroprevalence rate in both zones. The vaccinated group demonstrated a greater number of individuals testing positive for SARS-CoV-2 compared to the unvaccinated group. Conclusion The significant increase in the seroprevalence estimates in relation to the prior survey is because of the significant surge in COVID-19 vaccination coverage after the first wave of the pandemic. The findings of the study imply the dynamic nature of the pandemic and the different degrees of immunity obtained within the community. Ongoing surveillance and research are essential for refining effective strategies to manage and mitigate future pandemics effectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.